Use of adalimumab in poststreptococcal reactive arthritis.
Sánchez-Cano
Daniel
D
Unidad de Enfermedades Autoinmunes Sistémicas, Hospital Clínico San Cecilio, Granada, Spain. danielsanchezcano@supercable.es
Callejas-Rubio
José Luis
JL
Ortego-Centeno
Norberto
N
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D016918:Arthritis, Reactive / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D013290:Streptococcal Infections / Q000150:complications*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab